国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
International Journal of Urology and Nephrology
2015年
6期
915-919
,共5页
狼疮肾炎%瘦素%白细胞介素6%肿瘤坏死因子α
狼瘡腎炎%瘦素%白細胞介素6%腫瘤壞死因子α
랑창신염%수소%백세포개소6%종류배사인자α
Lupus Nephritis%Leptin%Interleukin-6%Tumor Necrosis Factor-alpha
目的 探讨血清瘦素和白细胞介素-6(interleukin-6,IL-6)及肿瘤坏死因子-α(TNF-α)在狼疮性肾炎(LN)患者中的变化及临床价值.方法 选择LN患者83例,根据系统性红斑狼疮疾病活动指数(SLE disease activity index,SLEDAI)对LN患者进行评分,并将其分为LN稳定期组(33例)和活动期组(50例).选择与LN患者性别、年龄和体重指数(Body Mass Index,BMI)均相匹配的健康体检者40例为对照组.采用放射免疫法测定血清瘦素水平,采用酶联免疫吸附法(Enzyme-linked immunosorbent Assay,ELISA)检测IL-6、TNF-α的水平,比较各组间的差异,分析血清瘦素和IL-6及TNF-α水平与一些临床指标间的关系.结果 LN患者血清瘦素和IL-6及TNF-α水平均高于健康对照组(P＜0.01);LN活动期组血清瘦素和IL-6及TNF-α水平均高于LN稳定期组与健康对照组(P＜0.01);LN稳定期组血清瘦素和IL-6及TNF-α水平与健康对照组比较,差异无统计学意义(P＞0.05).LN患者血清瘦素和IL-6及TNF-α水平与抗核抗体、ds-DNA抗体、抗核小体抗体、抗C1q抗体、SLEDAI评分、血沉、C反应蛋白、24h尿蛋白定量、血肌酐呈正相关(P＜0.05或P＜0.01);与补体C3、补体C4、内生肌酐清除率呈负相关(P ＜0.05或P＜0.01);血清瘦素与IL-6及TNF-α水平呈正相关(P＜0.05,P＜0.01).结论 瘦素和IL-6及TNF-α可能协同参与了LN的发病过程.动态检测LN患者血清瘦素和IL-6及TNF-α水平,可能有助于监测狼疮活动、评判病情轻重、选择治疗方案、观测疗效及判断预后.
目的 探討血清瘦素和白細胞介素-6(interleukin-6,IL-6)及腫瘤壞死因子-α(TNF-α)在狼瘡性腎炎(LN)患者中的變化及臨床價值.方法 選擇LN患者83例,根據繫統性紅斑狼瘡疾病活動指數(SLE disease activity index,SLEDAI)對LN患者進行評分,併將其分為LN穩定期組(33例)和活動期組(50例).選擇與LN患者性彆、年齡和體重指數(Body Mass Index,BMI)均相匹配的健康體檢者40例為對照組.採用放射免疫法測定血清瘦素水平,採用酶聯免疫吸附法(Enzyme-linked immunosorbent Assay,ELISA)檢測IL-6、TNF-α的水平,比較各組間的差異,分析血清瘦素和IL-6及TNF-α水平與一些臨床指標間的關繫.結果 LN患者血清瘦素和IL-6及TNF-α水平均高于健康對照組(P＜0.01);LN活動期組血清瘦素和IL-6及TNF-α水平均高于LN穩定期組與健康對照組(P＜0.01);LN穩定期組血清瘦素和IL-6及TNF-α水平與健康對照組比較,差異無統計學意義(P＞0.05).LN患者血清瘦素和IL-6及TNF-α水平與抗覈抗體、ds-DNA抗體、抗覈小體抗體、抗C1q抗體、SLEDAI評分、血沉、C反應蛋白、24h尿蛋白定量、血肌酐呈正相關(P＜0.05或P＜0.01);與補體C3、補體C4、內生肌酐清除率呈負相關(P ＜0.05或P＜0.01);血清瘦素與IL-6及TNF-α水平呈正相關(P＜0.05,P＜0.01).結論 瘦素和IL-6及TNF-α可能協同參與瞭LN的髮病過程.動態檢測LN患者血清瘦素和IL-6及TNF-α水平,可能有助于鑑測狼瘡活動、評判病情輕重、選擇治療方案、觀測療效及判斷預後.
목적 탐토혈청수소화백세포개소-6(interleukin-6,IL-6)급종류배사인자-α(TNF-α)재랑창성신염(LN)환자중적변화급림상개치.방법 선택LN환자83례,근거계통성홍반랑창질병활동지수(SLE disease activity index,SLEDAI)대LN환자진행평분,병장기분위LN은정기조(33례)화활동기조(50례).선택여LN환자성별、년령화체중지수(Body Mass Index,BMI)균상필배적건강체검자40례위대조조.채용방사면역법측정혈청수소수평,채용매련면역흡부법(Enzyme-linked immunosorbent Assay,ELISA)검측IL-6、TNF-α적수평,비교각조간적차이,분석혈청수소화IL-6급TNF-α수평여일사림상지표간적관계.결과 LN환자혈청수소화IL-6급TNF-α수평균고우건강대조조(P＜0.01);LN활동기조혈청수소화IL-6급TNF-α수평균고우LN은정기조여건강대조조(P＜0.01);LN은정기조혈청수소화IL-6급TNF-α수평여건강대조조비교,차이무통계학의의(P＞0.05).LN환자혈청수소화IL-6급TNF-α수평여항핵항체、ds-DNA항체、항핵소체항체、항C1q항체、SLEDAI평분、혈침、C반응단백、24h뇨단백정량、혈기항정정상관(P＜0.05혹P＜0.01);여보체C3、보체C4、내생기항청제솔정부상관(P ＜0.05혹P＜0.01);혈청수소여IL-6급TNF-α수평정정상관(P＜0.05,P＜0.01).결론 수소화IL-6급TNF-α가능협동삼여료LN적발병과정.동태검측LN환자혈청수소화IL-6급TNF-α수평,가능유조우감측랑창활동、평판병정경중、선택치료방안、관측료효급판단예후.
Objectives To investigate serum levels of leptin,interleukin-6 (IL-6),tumor necrosis factor-α (TNF-α) and its clinical value in lupus nephritis (LN) patients.Methods Eight-three patients with LN were divided into 2 groups(33 cases in inactive group and 50 cases in active group) according to SLEDAI (SLE disease activity index).To select 40 healthy people of matched sex,age and BMI(Body Mass Index) with LN Patients as The control group.Leptin levels were measured by radio immunoassay.IL-6,TNF-αlevels were measured by sandwich ELISA.The difference between groups and correlation of these parameters with clinical indicators were analysed.Results Leptin,IL-6,and TNF-αleves were significantly higher in the patients with LN than in the healthy controls (P ＜ 0.01);Lepin,IL-6,TNF-α in Active group in the patiens with LN were significantly higher than in the healthy controls and in the inactive group(P ＜ 0.01);There were no statistically differences to compare leptin,IL-6,TNF α levels with the health controls(P ＞0.05);The serum levels of lepin,IL-6,TNF-αare? positively correlated with ANA,anti-dsDNA,anti-nucleosome and anti-C1 q antibodies,SLEDAI score,ESR,C-reactive protein,24 hour urine protein,Serum creatinine (P ＜ 0.05 or P ＜ 0.01) and negatively correlated with complement C3,complement C4 and creatinine clearance(P ＜0.05 orP ＜0.01).The leptin are positively correlated IL-6 and TNF-α.Conclusions Leptin,IL-6 and TNF-α synergistically take part in the progress of LN.The dynamic observation of the levels of serum leptin,IL-6 and TNF-α contributes to monitor LN activity,evaluate the severity of desease,select treatment scheme,judge treatment affectiveness and prognosis.
